ライフサイエンスコーパス: initial dose

1 pled again 7 days later (196 hours after the initial dose).

2 econd dose (20 mg per kilogram regardless of initial dose).

3 to a lesser degree than that seen after the initial dose.

4 e considered for those not responding to the initial dose.

5 ee further doses at 4, 24 and 48 h after the initial dose.

6 be linear functions (reaction norms) of the initial dose.

7 ivation of these pathways than does the full initial dose.

8 educed MOG after she developed a rash at the initial dose.

9 e appearing 3 -9 days after receipt of their initial dose.

10 relative to placebo but were limited to the initial dose.

11 rmacokinetic studies were performed with the initial dose.

12 of a drug produce greater responses than the initial dose.

13 n cohorts 3 and 4 continued to receive their initial doses.

14 s with DME that did and did not receive such initial doses.

15 itch (24.5% vs. 31.5%) were less common with initial doses.

16 ed characteristics associated with receiving initial doses.

17 [3.1-8.2] ng/mL) (P<0.0001), despite similar initial doses.

18 ng a 93.3% tumor inhibition rate 12days post initial dosing.

19 f the first 24-h heartburn-free period after initial dosing.

20 Arm 1: prolonged-release tacrolimus (initial dose 0.2mg/kg/day); Arm 2: prolonged-release tac

21 ly x 3 doses followed by maintenance dosing (initial dose 0.6 mg/kg IV weekly).

22 ly, together with octreotide subcutaneously: initial dose 100 mug thrice daily and up to 200 mug thri

23 trial comparing oral mycophenolate mofetil (initial dose, 1000 mg per day, increased to 3000 mg per

24 tudy to identify a safe dose of rilotumumab (initial dose 15 mg/kg intravenously on day 1) plus ECX (

25 High-dose clopidogrel (600-mg initial dose, 150 mg daily thereafter) or standard-dose

26 By day 30 after initial dosing, 17 were recovered, 2 were still hospital

27 By day 30 after initial dosing, 17/23 were recovered, 2/23 were still ho

28 s via subcutaneously implanted osmotic pump (initial dose 2.0 mg/kg/day, free base).

29 irregular treatment interval cohort without initial doses (- 2.5 letters; P = 0.365 vs baseline) at

30 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks

31 eceive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [in

32 ose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg

33 nd irregular treatment interval cohorts with initial doses (+ 4.9 and + 4.0 letters, respectively; P

34 tide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [in

35 ose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or p

36 b (6 mg/kg once every 2 weeks) or cetuximab (initial dose 400 mg/m(2); 250 mg/m(2) once a week therea

37 were randomized to receive CsA (19 patients, initial doses 5 mg/kg/d) or matched placebo (20 patients

38 Two years after initial dosing, 571 patients (76.7%) remained on therapy

39 erically higher for eyes with versus without initial doses (63.0 [18.1] vs. 62.5 [19.8] letters); thi

40 0% of the patients had been placed on excess initial doses according to the 2011 guidelines, and 47%

41 7% of the patients had been placed on excess initial doses according to the 2016 guidelines.

42 umab treatment but discontinued it after the initial dose) according to the administration status of

43 The initial doses administered were cisplatin 75 mg/m(2) eve

44 lowed by 0.5 mg orally within 2 hours of the initial dose and 0.5 mg orally twice a day for 14 days o

45 were freedom from pain at 2 hours after the initial dose and absence of the most bothersome migraine

46 ntiation that is absolutely dependent on the initial dose and affinity of peptide presented to a naiv

47 avenous tyramine were assessed following the initial dose and after 1 and 2 weeks of drug administrat

48 in STAZN-treated rats, within 1-1.5 h of the initial dose and fell to a median score of 3 at 72 h, co

49 emain the primary treatment, but the optimal initial dose and tapering treatment regimens are unknown

50 isual outcomes than patients who received no initial doses and an irregular treatment regimen.

51 al that an optimal vaccine regimen of higher initial doses and lower final doses may lead to a reduct

52 Initial doses and schedules for cycle 1 consisted of OXP

53 t variants PEO1/OlaJR, established by higher initial doses and short-term PARPi treatment, develops P

54 Despite no difference in initial doses and time to reach 90% blockade or clinical

55 ous nanorod concentrations rose rapidly upon initial dosing and then fell to stable levels over the c

56 on ranged from 0.5 to 2.4 mg/L, depending on initial dosing and time.

57 It was shown that this conservative initial dosing approach, which guarantees renal safety,

58 ers and transmit efficiently irrespective of initial dose are key characteristics distinguishing IAVs

59 splant recipients with minimal risk when low initial doses are used (25 mug/kg; 1.5 mg if >/=60 kg) a

60 For small initial doses, as one would naturally expect to occur, t

61 ed platelet aggregation at 2 hours after the initial dose at 2 and 4 weeks was 15%, 8%, and 11% in th

62 Initial dose at the time of transplantation was 5 mg/kg

63 ) in 28-day-old rats tested 7 days after the initial dose, but did enhance the effects of a lower (0.

64 yses, in addition of smoking and epinephrine initial dose, cardiac troponin I (odds ratio 3.58 [2.03-

65 hed to sublingual spitting, resumed with the initial dose cautiously, and were able to continue.

66 ged TAFs and inhibited tumor growth after an initial dose, chronic exposure to cisplatin NP led to el

67 d all patients have now been enrolled in the initial dose cohort (2 x 10(11) vg/kg).

68 aining endosomes that are dependent on these initial dosing conditions.

69 rculation after 4h varies from 10% to 85% of initial dose, depending on the block copolymer.

70 /CT scans obtained at a median of 2 mo after initial dosing did not demonstrate significant changes i

71 eated doses of RNA-LNP are administered, the initial dose does not affect the editing efficiency and

72 , 8, and 15 of each 28-day cycle (20 mg/m(2) initial dose, escalated to 70 mg/m(2) thereafter) and de

73 Initial dose escalation in the UES group was followed by

74 Methods: The initial dose escalation phase of this first-in-humans pr

75 In 89 evaluable patients, the initial dose escalation strategy significantly reduced t

76 In the initial dose-escalation phase 1 stage of the trial, pati

77 The initial dose-escalation phase established 25 mg twice da

78 In the initial dose-escalation phase, 25 patients with adenocar

79 Initial dose-escalation, build-up, and maintenance phase

80 b 6.0 mg up to every 16 weeks (Q16W) after 4 initial doses every 4 weeks (Q4W) or aflibercept 2.0 mg

81 Patients in the faricimab arm received 4 initial doses every 4 weeks through week 12.

82 ept 2 mg every 8 weeks for 52 weeks, after 5 initial doses every 4 weeks.

83 9 in the dose escalation cohort and 23 in an initial dose expansion cohort.

84 tumors at doses of 116 mg/m(2)/d during the initial dose-finding period.

85 In an initial dose-finding study (substudy A), 6 women and 4 m

86 In initial dose-finding trials, pediatric-specific cohorts

87 A treatment regimen consisting of a high initial dose followed by an extended tapering of doses i

88 The median (IQR) initial dose followed by remission was 50 (50-100) mg/d.

89 plus weekly doses of cetuximab: 400 mg/m(2) initial dose, followed by seven weekly doses at 250 mg/m

90 nded to be higher in association with higher initial doses (for initial doses <40 mg of prednisone pe

91 libercept 2.0 mg every 8 weeks (Q8W) after 3 initial doses given Q4W.

92 10 JAU with the same target dose in the high initial dose group (18 patients).

93 In the low initial dose group (33 patients), the initial dose of st

94 ith polyneuropathy, three in each of the two initial dose groups (0.1 mg per kilogram and 0.3 mg per

95 Within 24 h of infusion, 20% of the initial dose homed to the bone marrow and spleen and dis

96 t was relapse-free efficacy at 6 months from initial dose (ie, clearance of initial infection without

97 in S6c induced transient vasodilation at the initial dose in rings from sham-treated rats but not lip

98 ime dosing nomogram based on eGFR cr-cys for initial dosing in the critically ill.

99 ock waves causes less tissue trauma when the initial dose is followed by a brief (3-4 min) pause in s

100 e heart failure treatment (AHF), its optimal initial dose is unclear.

101 ia and grade 3 fatigue) were reported in the initial dose level (lenvatinib 24 mg/d plus pembrolizuma

102 The initial dose level consisted of doxorubicin 75 mg/m(2) o

103 The initial dose level in arm 2 was above the MTD.

104 cologic pain management utilization prior to initial dose level in patients starting long-term opioid

105 The initial dose level of cisplatin was 30 mg/m(2), escalate

106 In the low-GFR cohort, at the initial dose level using 12 mCi/kg of 131I-MIBG and redu

107 The initial dose level was 100 mg/m(2)/d with intrapatient d

108 mide once daily on days 1 to 21 (4 mg as the initial dose level), and dexamethasone (40 mg oral or IV

109 At the initial dose level, one of six patients developed febril

110 All patients were treated with the initial dose level, then the RP2D.

111 The initial dose levels were 2-CdA 0.1 mg/kg/d by continuous

112 n association with higher initial doses (for initial doses <40 mg of prednisone per day: RR, 3.23; 95

113 Although eyes with frequent initial doses maintained higher VA than those without, t

114 Eyes treated with an initial dose of >=4 times daily were more likely to achi

115 imaging data of patients who received their initial dose of (177)Lu-PSMA-617 between March 2022 and

116 retinopathy of prematurity (ROP), down to an initial dose of 0.004 mg.

117 administered by subcutaneous injection at an initial dose of 0.05 mg per kilogram of body weight ever

118 Four patients were enrolled at an initial dose of 0.3 mg.

119 ses of terlipressin (TERLI-BOL group) at the initial dose of 0.5 mg every 4 hours.

120 ated with oral risperidone for 4 weeks at an initial dose of 1 mg/day that was titrated as necessary

121 CDP571 at an initial dose of 10 or 20 mg/kg is safe and effective for

122 ovel oral anticoagulants such as dabigatran (initial dose of 110 mg within 1-4 h after surgery, follo

123 After an initial dose of 12 x 10(9) PFU/m(2), patients tolerated

124 a 1:1 ratio to receive chlorthalidone at an initial dose of 12.5 mg per day, with increases every 4

125 These data suggest that an initial dose of 162 mg aspirin may be as effective as an

126 ntravenous infusion (TERLI-INF group) at the initial dose of 2 mg/day or intravenous boluses of terli

127 er, received intravenous pembrolizumab at an initial dose of 2 mg/kg every 3 weeks.

128 cipants were randomly assigned to receive an initial dose of 200,000 IU oral vitamin D3, then 200,000

129 Oral vitamin D3 in an initial dose of 200000 IU, followed a month later by mon

130 g/m2 followed by a continuous infusion at an initial dose of 30 mg/m2/d for 48 hours.

131 the burn, the conscious animals received an initial dose of 4 mL x kg(-1) HSD (n = 6) or normal sali

132 Eyes treated with an initial dose of 4 times daily were more likely to achiev

133 6.5 mmol per liter received patiromer (at an initial dose of 4.2 g or 8.4 g twice a day) for 4 weeks

134 y plus weekly cetuximab (211 patients) at an initial dose of 400 mg per square meter of body-surface

135 ceived either pleconaril 200 mg twice daily (initial dose of 400 mg) or placebo for 7 days.

136 Patients were treated with cetuximab at an initial dose of 400 mg/m(2), followed by 250 mg/m(2) wee

137 Ponatinib was administered at an initial dose of 45 mg once daily.

138 iclovir was administered intravenously at an initial dose of 5 mg/kg/d and then increased to 10 mg/kg

139 aise the question of whether the recommended initial dose of 5-FU-based chemotherapy for women should

140 d to sertraline (n = 102) for 12 weeks at an initial dose of 50 mg/d (escalated to a maximum dose of

141 Four healthy patients received an initial dose of 500-mg azithromycin followed by 250-mg d

142 AML patients were treated with CEP-701 at an initial dose of 60 mg orally twice daily.

143 received 9.95 GBq 131I-MN-14 F(ab)2, for an initial dose of 656 cGy to critical organs, 8 received 9

144 ID/OCT group received midodrine orally at an initial dose of 7.5 mg thrice daily, with the dose incre

145 tients in two sequential cohorts received an initial dose of 7.5 or 9.4 mg of imetelstat per kilogram

146 d 4 to 6 weeks after chemoradiotherapy at an initial dose of 75 mg/m2.

147 enhances hepatic transgene expression at the initial dose of AAV vector, independent of its effects o

148 eanwhile, a second immunization or a reduced initial dose of Ad26.COV2.S induces lower activation of

149 Two to six hours after the initial dose of alpha-MPT, concentrations of alpha-MPT w

150 Even at 25% of the initial dose of amidine-oxime (i.e., a dose of 36 mumol/

151 schema for combination therapy such that an initial dose of Apo2L/TRAIL would precede administration

152 Buprenorphine initiation with an initial dose of at least 2 mg of sublingual buprenorphin

153 DTPA)(30)-enhanced MR imaging followed by an initial dose of bevacizumab or saline (as a control).

154 Patients received an initial dose of cetuximab (400 mg/m(2)) on day 1 of week

155 An initial dose of cetuximab 400 mg/m2 intravenously was ad

156 The initial dose of CPT-11 was 125 mg/m2 given as a weekly 9

157 cy being dependent not only on delivering an initial dose of drug sufficient to achieve receptor satu

158 Fourteen hours after receiving the initial dose of either pleconaril or placebo, subjects w

159 The corresponding recommended initial dose of FK506 for kidney transplant recipients i

160 The corresponding recommended initial dose of FK506 for kidney transplant recipients s

161 The initial dose of gemcitabine was 20 mg/m(2) by 30-minute

162 ients with Crohn's disease who respond to an initial dose of infliximab are more likely to be in remi

163 hildren received IIV followed by LAIV, 13 an initial dose of LAIV, and 11 a second dose of LAIV.

164 uenza viral strains were recovered after the initial dose of LAIV.

165 The initial dose of lenalidomide used (25 mg/d) was poorly t

166 ed by electroretinography 72 hours after the initial dose of methanol and after a 72-hour recovery pe

167 Tacrolimus in combination with an initial dose of MMF 2 g/day is a very effective and safe

168 The mean initial dose of MMF was 0.92 g/d (range, 0.5 to 2 g/d).

169 ted before and after in vivo exposure to the initial dose of OFA therapy in 25 patients undergoing th

170 redefined escalating dose schedule-after the initial dose of once-daily 350 mug Triac, the daily dose

171 For the induction dose of hypnotics and the initial dose of other drugs that have a fast onset of ef

172 The initial dose of paclitaxel was 170 mg/m2, and this was e

173 The initial dose of paclitaxel was 30 mg/m2 by 3-hour intrav

174 to estimate vaccine effectiveness (VE) of an initial dose of pH1N1 monovalent vaccine in children age

175 without aura, in a 1:1:1 ratio to receive an initial dose of placebo, ubrogepant at a dose of 50 mg,

176 ion or immediately after reperfusion with an initial dose of PNU-101017 (30 mg/kg i.p.) or diazepam (

177 s because they are able to tolerate a higher initial dose of radiation.

178 d before and 4 hours after initiation of the initial dose of rituximab in 21 lymphoma subjects.

179 blood of a host, following inhalation of an initial dose of spores.

180 he low initial dose group (33 patients), the initial dose of standardized house dust mite extract was

181 mL collagen was measured over time after the initial dose of study drug and at 1 and 2 weeks of chron

182 mL collagen was measured over time after the initial dose of study drug and at days 14 and 28 of long

183 ' self-reported pain within 5 minutes of the initial dose of sublingual or spray nitroglycerin.

184 y transplantation or retransplantation to an initial dose of tacrolimus BD 0.2 mg/kg per day (Arm 1;

185 pilumab, or mepolizumab and had received the initial dose of the 2-dose adult SARS-CoV-2 mRNA vaccine

186 nt >10 x 10(9) cells per L) could receive an initial dose of the immunoconjugate gemtuzumab ozogamici

187 The initial dose of vinorelbine 30 mg/m2 was administered as

188 oses of 3 mg/kg, 10 mg/kg, or 30/10 mg/kg (2 initial doses of 30 mg/kg, followed by 10 mg/kg) on days

189 A fifth cohort of two participants received initial doses of 900 mg.

190 nimals were inoculated intranasally with the initial doses of bacterial suspension.

191 We recommend that initial doses of CAF be computed according to actual bod

192 Febrile neutropenic patients should receive initial doses of empirical antibacterial therapy within

193 Corresponding initial doses of FK506 were 0.2, 0.3, and 0.4 mg/kg/day.

194 Corresponding initial doses of FK506 were 0.2, 0.3, or 0.4 mg(kg/day,

195 Initial doses of OKT3 are associated with a cytokine-ind

196 sequentially assigned to receive escalating initial doses of sirolimus (0.5-7.0 mg/m2/day), in addit

197 ible US population had taken the recommended initial doses of the COVID-19 vaccines as of April 2022.

198 stinal adverse events with onset 2-5 h after initial doses of the vaccine, similar to those caused by

199 Our methodology involves the initial dosing of a chemical probe such as carbon monoxi

200 in clearance rates with higher-than-approved initial dosing of risankizumab with prolonged maintenanc

201 kin biopsies performed both before and after initial dosing of that patient revealed less fibrosis an

202 afety profile of sunitinib 50 mg once-daily (initial dose) on schedule 4-2 was manageable and efficac

203 12.2 +/- 3.9 kPa) over the 96 hrs after the initial dose (p = .021 by repeated-measures analysis of

204 These initial dosing patterns remained remarkably consistent u

205 s with nAMD to be rapidly extended after the initial dosing phase while maintaining visual gains thro

206 In this initial, dose-ranging, 12-week study, treatment with rhv

207 both the initial 90Y femur activity and the initial dose rate from external 137Cs gamma rays with 5.

208 9-AC was infused over 72 hours at an initial dose rate of 40 microg/m2/h every 3 weeks with s

209 Initial dose rates ranging from 0.01-30 cGy/hr can be de

210 y decreasing dose rates of 137Cs gamma rays, initial dose rates required to achieve 37% survival were

211 Using the calibrated dosimeter, the initial dose rates to the marrow per unit of injected ac

212 etups and overlooks dose heterogeneity, with initial dose rates varying by up to 2.3-fold based on cl

213 Based on modelling results, Eyes with initial doses received more injections (mean [standard d

214 Variant allele carriers received an initial dose reduction of >/= 50% followed by dose titra

215 and VKORC1 that suggest he might have a low initial dosing requirement for warfarin.

216 Using human monocyte cell line (THP-1), initial dose-response experiments were conducted to dete

217 ion of seizures, time to first seizure after initial dose stabilisation), and adverse events (inciden

218 In an initial dose-testing phase we found a Guanfacine dose th

219 race were less likely (P < 0.01) to receive initial doses than White patients, as were Medicare/Medi

220 days of standard-dose cetuximab (400 mg/m(2) initial dose, then 250 mg/m(2) per week) plus irinotecan

221 Characteristics and outcomes for eyes with initial doses (three injections within 100 days of index

222 ng a kinetic model, we uncovered a nonlinear initial dose threshold that is dependent on the amount o

223 examination was performed 24 hours after the initial dose to enable calculation of the acute change i

224 toneal injection at doses ranging from 62.5 (initial dose) to 25 mg/kg.

225 tients remained on their originally assigned initial dose up to 48 weeks.

226 esearch may elucidate the impact of frequent initial doses versus total injection number on DME outco

227 high initial dosage group (17 patients), the initial dose was 10 JAU but the target dose at the end o

228 The initial dose was 20 mCi and escalation was in 20-mCi inc

229 The initial dose was 25 mg, with subsequent escalations to 3

230 The initial dose was 300 mg orally in a single daily dose fo

231 Initial dose was 5 mg daily with 1 dose titration at wee

232 The initial dose was 75 mg/m2 with G-CSF 5 micrograms/kg.

233 The initial dose was based on the average epoetin dose given

234 This initial dose was followed by a continuous apyrase infusi

235 Next, the initial dose was increased to 10 JAU with the same targe

236 nto hydrogels, a maximum of about 60% of the initial dose was released within 7days to 21days.

237 f the first 24-h heartburn-free period after initial dosing was 2.0 (+/- 2.2) days for Gaviscon(R) an

238 d failure risk ratio (weight-based v reduced initial doses) was 0.73 (95% confidence interval, 0.53 t

239 Initial doses were closely similar at admission for both

240 nta with a total accumulation of 2.8% of the initial dose, which corresponds to a 94 fold increase in

241 ed a second dose of ZVL >=10 years after the initial dose with de novo-immunized age-matched controls

242 weeks, whereas 27 received 3 mg/kg as their initial dose with subsequent doses reduced to 1 mg/kg ev

243 In contrast, PEO1/OlaR, developed by lower initial doses with long-term PARPi exposure, shows no re